Verbruggen B - Search Results

1

Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy.

de Mast Q, de Groot PG, van Heerde WL, Roestenberg M, van Velzen JF, Verbruggen B, Roest M, McCall M, Nieman AE, Westendorp J, Syafruddin D, Fijnheer R, van Dongen-Lases EC, Sauerwein RW, van der Ven AJ. de Mast Q, et al. Among authors: verbruggen b. Br J Haematol. 2010 Dec;151(5):495-503. doi: 10.1111/j.1365-2141.2010.08399.x. Epub 2010 Oct 19. Br J Haematol. 2010. PMID: 20955404 Free article.

2

Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.

Boekhorst J, Verbruggen B, Lavergne JM, Costa JM, Schoormans SC, Brons PP, van Kraaij MG, Nováková IR, van Heerde WL. Boekhorst J, et al. Among authors: verbruggen b. Br J Haematol. 2005 Oct;131(1):109-17. doi: 10.1111/j.1365-2141.2005.05737.x. Br J Haematol. 2005. PMID: 16173970 Free article.

3

Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.

Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Verbruggen B, et al. Semin Thromb Hemost. 2009 Nov;35(8):752-9. doi: 10.1055/s-0029-1245107. Epub 2010 Feb 18. Semin Thromb Hemost. 2009. PMID: 20169511 Review.

4

A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis.

van Geffen M, Loof A, Lap P, Boezeman J, Laros-van Gorkom BA, Brons P, Verbruggen B, van Kraaij M, van Heerde WL. van Geffen M, et al. Among authors: verbruggen b. Hematology. 2011 Nov;16(6):327-36. doi: 10.1179/102453311X13085644680348. Hematology. 2011. PMID: 22183066 Free article.

5

Diagnosis of factor VIII deficiency.

Verbruggen B, Meijer P, Novákova I, Van Heerde W. Verbruggen B, et al. Haemophilia. 2008 Jul;14 Suppl 3:76-82. doi: 10.1111/j.1365-2516.2008.01715.x. Haemophilia. 2008. PMID: 18510526 Review.

6

Methodological shortcomings in assessment of factor VIII concentrate inhibition.

Verbruggen B, van Heerde W, Budde U. Verbruggen B, et al. Haemophilia. 2007 Sep;13(5):680-1. doi: 10.1111/j.1365-2516.2007.01529.x. Haemophilia. 2007. PMID: 17880465 No abstract available.

7

A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.

Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. Verbruggen B, et al. Thromb Haemost. 2002 Aug;88(2):362-4. Thromb Haemost. 2002. PMID: 12195715 No abstract available.

8

Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction.

Dardikh M, Albert T, Masereeuw R, Oldenburg J, Novakova I, van Heerde WL, Verbruggen B. Dardikh M, et al. Among authors: verbruggen b. J Thromb Haemost. 2012 Apr;10(4):706-8. doi: 10.1111/j.1538-7836.2012.04645.x. J Thromb Haemost. 2012. PMID: 22284849 Free article. No abstract available.

9

Diagnosis and quantification of factor VIII inhibitors.

Verbruggen B. Verbruggen B. Haemophilia. 2010 May;16(102):20-4. doi: 10.1111/j.1365-2516.2008.01924.x. Epub 2009 Feb 18. Haemophilia. 2010. PMID: 19228204

10

The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.

Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I. Verbruggen B, et al. Thromb Haemost. 2001 Dec;86(6):1435-9. Thromb Haemost. 2001. PMID: 11776311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters